The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: The payer perspective

Managed Care Interface

Volumn 20, Issue 1, 2007, Pages 23-34

  McKinnon, Peggy S ^a   Carter, Chureen T ^b   Girase, Prafulla G ^b   Liu, Larry Z ^c   Carmeli, Yehuda ^d  

^a BARNES JEWISH HOSPITAL   (United States)

^b PharMetrics Inc   (United States)

^c PFIZER INC   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT CARE; SKIN INFECTION; SOFT TISSUE INFECTION;

ACETAMIDES; ADULT; AMBULATORY CARE; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; OXAZOLIDINONES; VANCOMYCIN;

EID: 33846439348     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Engemann JJ, Carmeli Y, Cosgrove SE, et al: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598.
2. Sharpe JN, Shively EH, Polk Jr HC: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg 2005;189:425-428.
3. Weigelt J, Itani K, Stevens D, et al: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005;49:2260-2266.
4. Itani KM, Weigelt J, Li JZ, et al: Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2005;26:442-448.
5. McKinnon PS, Sorensen SV, Liu LZ, et al: Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA-complicated skin and soft tissue infections. Ann Pharmacoter 2006;40:1017-1023.
6. Li JZ, Willke RJ, Rittenhouse BE, et al: Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: Results from a randomized clinical trial. Surg infect 2003;4:57-70.
7. Li JZ, Willke RJ, Pinto LA, et al: Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial. Pharmacotherapy 2001; 21:263-274.
8. Nathwani D, Li JZ, Balan DA, et al: An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious gram-positive bacterial infections: The importance of treatment setting in evaluating treatment effects. Int J Antimicrob Agents 2004;23:315-324.
9. D'Agostino Jr RB: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
10. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-763.
11. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40:373-383.
12. Tice AD, Hoaglund PA, Nolet B, et al: Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22(suppl):63-70.
13. McCollum M, Rhew DC, Parodi S: Cost analysis of switching from i.v. vancomycin to p.o. linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003;25:3173-3189.
14. Paladino JA, Sperry HE, Backes JM, et al: Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991;91:462-470.
15. Parodi S, Rhew DC, Goetz MB: Early switch and early discharge opportunities in intravenous vancomycin treatment of suspected methicillin-resistant staphylococcal species infections. J Manag Care Pharm 2003;9:317-326.
16. Przybylski KG, Rybak MJ, Martin PR, et al: A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997;17:271-276.
17. Carmeli Y, Mozaffari E: Use of insurance claims data to assess outpatient antimicrobial therapy for gram-positive infections. Pharmacotherapy 2002;22(suppl):55-62.
18. Graboyes RF: Medical care price indexes. Economic Quarterly 1994;80:69-89.